Literature DB >> 19912985

Generation of human induced pluripotent stem cells from a Bombay individual: moving towards "universal-donor" red blood cells.

Ali Seifinejad1, Adeleh Taei, Mehdi Totonchi, Hamed Vazirinasab, Seideh Nafiseh Hassani, Nasser Aghdami, Ebrahim Shahbazi, Reza Salman Yazdi, Ghasem Hosseini Salekdeh, Hossein Baharvand.   

Abstract

Bombay phenotype is one of the rare phenotypes in the ABO blood group system that fails to express ABH antigens on red blood cells. Nonsense or missense mutations in fucosyltransfrase1 (FUT1) and fucosyltransfrase2 (FUT2) genes are known to create this phenotype. This blood group is compatible with all other blood groups as a donor, as it does not express the H antigen on the red blood cells. In this study, we describe the establishment of human induced pluripotent stem cells (iPSCs) from the dermal fibroblasts of a Bombay blood-type individual by the ectopic expression of established transcription factors Klf4, Oct4, Sox2, and c-Myc. Sequence analyses of fibroblasts and iPSCs revealed a nonsense mutation 826C to T (276 Gln to Ter) in the FUT1 gene and a missense mutation 739G to A (247 Gly to Ser) in the FUT2 gene in the Bombay phenotype under study. The established iPSCs resemble human embryonic stem cells in morphology, passaging, surface and pluripotency markers, normal karyotype, gene expression, DNA methylation of critical pluripotency genes, and in-vitro differentiation. The directed differentiation of the iPSCs into hematopoietic lineage cells displayed increased expression of the hematopoietic lineage markers such as CD34, CD133, RUNX1, KDR, alpha-globulin, and gamma-globulin. Such specific stem cells provide an unprecedented opportunity to produce a universal blood group donor, in-vitro, thus enabling cellular replacement therapies, once the safety issue is resolved. Copyright 2009 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19912985     DOI: 10.1016/j.bbrc.2009.11.058

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  9 in total

Review 1.  Induced pluripotent stem cells: emerging techniques for nuclear reprogramming.

Authors:  Ji Woong Han; Young-Sup Yoon
Journal:  Antioxid Redox Signal       Date:  2011-05-05       Impact factor: 8.401

2.  A Very Rare Case with Particular H-deficient Phenotypes.

Authors:  Min Song; Shuming Zhao; Tianlun Jiang; Hua Lu
Journal:  Indian J Hematol Blood Transfus       Date:  2018-01-11       Impact factor: 0.900

3.  A Novel Insight into Endothelial and Cardiac Cells Phenotype in Systemic Sclerosis Using Patient-Derived Induced Pluripotent Stem Cell.

Authors:  Sedigheh Gholami; Zahra Mazidi; Sara Pahlavan; Fariba Moslem; Mahya Hosseini; Adeleh Taei; Mahdi Hesaraki; Maryam Barekat; Nasser Aghdami; Hossein Baharvand
Journal:  Cell J       Date:  2021-07-17       Impact factor: 2.479

4.  Cellular Reprogramming toward the Erythroid Lineage.

Authors:  Laura J Norton; Alister P W Funnell; Richard C M Pearson; Merlin Crossley
Journal:  Int J Cell Biol       Date:  2011-07-26

5.  Generation and characterization of erythroid cells from human embryonic stem cells and induced pluripotent stem cells: an overview.

Authors:  Kai-Hsin Chang; Halvard Bonig; Thalia Papayannopoulou
Journal:  Stem Cells Int       Date:  2011-10-26       Impact factor: 5.443

6.  Differentiation potential of o bombay human-induced pluripotent stem cells and human embryonic stem cells into fetal erythroid-like cells.

Authors:  Fatemeh Ganji; Saeid Abroun; Hossein Baharvand; Nasser Aghdami; Marzieh Ebrahimi
Journal:  Cell J       Date:  2015-01-13       Impact factor: 2.479

7.  Enhancement of red blood cell transfusion compatibility using CRISPR-mediated erythroblast gene editing.

Authors:  Joseph Hawksworth; Timothy J Satchwell; Marjolein Meinders; Deborah E Daniels; Fiona Regan; Nicole M Thornton; Marieangela C Wilson; Johannes Gg Dobbe; Geert J Streekstra; Kongtana Trakarnsanga; Kate J Heesom; David J Anstee; Jan Frayne; Ashley M Toye
Journal:  EMBO Mol Med       Date:  2018-06       Impact factor: 12.137

8.  Alternative blood products and clinical needs in transfusion medicine.

Authors:  Carolyn Whitsett; Stefania Vaglio; Giuliano Grazzini
Journal:  Stem Cells Int       Date:  2012-04-08       Impact factor: 5.443

9.  Qualitative and quantitative comparison of the proteome of erythroid cells differentiated from human iPSCs and adult erythroid cells by multiplex TMT labelling and nanoLC-MS/MS.

Authors:  Kongtana Trakarnsanga; Marieangela C Wilson; Rebecca E Griffiths; Ashley M Toye; Lee Carpenter; Kate J Heesom; Steve F Parsons; David J Anstee; Jan Frayne
Journal:  PLoS One       Date:  2014-07-14       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.